FDA approves Xgeva (denosumab) for the prevention of skeletal-related events in patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved Amgen’s supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients…